Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects.
about
New and emerging treatments for epilepsy: review of clinical studies of lacosamide, eslicarbazepine acetate, ezogabine, rufinamide, perampanel, and electrical stimulation therapyRetigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.Ezogabine: a new angle on potassium gates.Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizuresNeuronal potassium channel openers in the management of epilepsy: role and potential of retigabine.Clinical utility of adjunctive retigabine in partial onset seizures in adults.Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy.Efficacy of retigabine in adjunctive treatment of partial onset seizures in adults.Drug interactions involving the new second- and third-generation antiepileptic drugs.Pharmacotherapy of epilepsy: newly approved and developmental agents.Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy.Novel medications for epilepsy.Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.Retigabine for partial onset seizures.Ezogabine: an evaluation of its efficacy and safety as adjunctive therapy for partial-onset seizures in adults.Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel.Practical Use of Newer Antiepileptic Drugs as Adjunctive Therapy in Focal Epilepsy.Retigabine (ezogabine) as add-on therapy for partial-onset seizures: an update for clinicians.
P2860
Q27007942-724E0E97-31FB-4336-8A60-33594B58EE90Q34333196-6ACB994B-18D6-4A65-92ED-5D31573CFBEEQ35052160-57DC071B-9A6D-48C2-8573-C88A76A20453Q35117817-AC43E707-43B4-4F4B-A4AF-140F98EBC85BQ35683922-B02AA39C-15B0-4BA8-94A0-B782F129C88CQ35717049-BD1D6BBB-EA52-4528-AD30-70E35F57BBF0Q36144410-59CD6848-B5C2-4B67-B835-41C464EFE0F4Q37302567-825F6EA7-229C-4AC8-8AB6-2181D9371F09Q37658910-0C7FBCF5-4008-462F-9D8F-F52D165D5F87Q37831297-FA4E75FF-7C9E-49B9-AE2B-A00E9976B9E3Q37936428-41FF9E01-AF97-4D1C-8684-2A4B94F86299Q37950518-8B2CDC1A-637B-466E-B3E5-802843573649Q37992162-93313EAA-5B82-4035-B0B8-962348F4B324Q38006978-79B9AB8B-0FC1-4A58-B0D5-3C3EEBF9D951Q38044694-A70C249F-C7E4-40AE-A415-DB7EBC3ED9B1Q38115721-B1D19AA7-1162-4A9D-ACAE-CA7487058824Q38123853-25B79653-DF27-4FD5-AB9C-6374A546645AQ38617833-F9D4C570-5463-4237-836E-866DCF76BA40Q42385228-25D474ED-030F-42A1-A231-553FDDB98612
P2860
Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Lack of pharmacokinetic intera ...... ady-state in healthy subjects.
@en
Lack of pharmacokinetic intera ...... ady-state in healthy subjects.
@nl
type
label
Lack of pharmacokinetic intera ...... ady-state in healthy subjects.
@en
Lack of pharmacokinetic intera ...... ady-state in healthy subjects.
@nl
prefLabel
Lack of pharmacokinetic intera ...... ady-state in healthy subjects.
@en
Lack of pharmacokinetic intera ...... ady-state in healthy subjects.
@nl
P2093
P2860
P1476
Lack of pharmacokinetic intera ...... ady-state in healthy subjects.
@en
P2093
Alain Patat
Geraldine M Ferron
Paul Rolan
Steven M Troy
Virginia Parks
P2860
P356
10.1046/J.1365-2125.2003.01825.X
P407
P577
2003-07-01T00:00:00Z